Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma.
BACKGROUND
Neovascular glaucoma (NVG) is a type of secondary angle-closure glaucoma that can result from severe retinal ischemia, such as proliferative diabetic retinopathy. Vascular endothelial growth factor (VEGF) plays a role in ocular neovascularization, which can result in NVG. The use of bevacizumab, an anti-VEGF antibody, has been shown to lead to the rapid resolution of ocular neovascularization and may be used off-label in conjunction with panretinal photocoagulation in the treatment of neovascular glaucoma.


METHODS
A 71-year-old man presented with neovascular glaucoma in both eyes secondary to proliferative diabetic retinopathy and was treated with both panretinal photocoagulation and an intravitreal injection of bevacizumab, which led to the rapid resolution of his iris neovascularization. A follow-up examination after 12 months showed that there was no recurrence of neovascularization.


CONCLUSIONS
This case shows the possible beneficial effects of bevacizumab in conjunction with panretinal photocoagulation as a treatment option for neovascular glaucoma.
Wasik
Alyon
A
Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, USA. alyon.wasik@va.gov
Song
Huey-Fen
HF
Grimes
Amy
A
Engelke
Carla
C
Thomas
Abby
A
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008028:Light Coagulation; D008297:Male; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab